SecBot SecBot
SECBOTREPLAY Home › Report › SBFM

SBFM · Sunshine Biopharma's 2026 proxy statement seeks shareholder approval to…

Sunshine Biopharma Inc. · DEF 14A filed Nov 12, 2026 at 16:05 ET

At the news

BEARISHIMPACT 5/10

DEF 14A filed Nov 12, 2026 at 16:05 ET

Sunshine Biopharma's 2026 proxy statement seeks shareholder approval to increase the 2023 Equity Incentive Plan share reserve from 3,415 to 7,000,000 shares, a massive 2,050x increase. The company has no shares remaining under the plan, and the CEO holds 130,000 Series B Preferred shares with 1,000 votes each, giving him effective control over all voting matters. The company has sustained net losses of $5.98M in 2025, $5.13M in 2024, and $4.51M in 2023, with zero total shareholder return over three years.

  • Proposal to increase 2023 Equity Incentive Plan shares from 3,415 to 7,000,000 shares (a 2,050x increase)
  • CEO Dr. Steve Slilaty holds 130,000 Series B Preferred shares with 1,000 votes each, giving him 130 million votes vs. 823,772 common shares outstanding
  • No shares currently available under the 2023 Plan; all 3,415 previously authorized shares were issued to one director in 2026
  • Net losses: ($5,975,352) in 2025, ($5,134,116) in 2024, ($4,506,044) in 2023

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access